These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 20109425)

  • 1. Acute coronary syndrome in a young woman treated with sibutramine.
    Gómez-Barrado JJ; Turégano S; Garcipérez de Vargas FJ; Porras Y
    Rev Esp Cardiol; 2010 Feb; 63(2):243. PubMed ID: 20109425
    [No Abstract]   [Full Text] [Related]  

  • 2. A sibutramine-induced delusional disorder relapse.
    Fernández P; Peiró AM
    J Neuropsychiatry Clin Neurosci; 2007; 19(1):88-9. PubMed ID: 17308238
    [No Abstract]   [Full Text] [Related]  

  • 3. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ; Wilton LV; Shakir SA
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [No progress without the physician in therapy of obesity].
    Schmidt H; Plauth M
    MMW Fortschr Med; 2000 Jan; 142(4):35-6. PubMed ID: 10850095
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sibutramine-induced acute myocardial infarction in a young lady.
    Yim KM; Ng HW; Chan CK; Yip G; Lau FL
    Clin Toxicol (Phila); 2008 Nov; 46(9):877-9. PubMed ID: 18788006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of sibutramine to treat obesity.
    Ryan DH
    Prim Care; 2003 Jun; 30(2):405-26, viii. PubMed ID: 14567156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of QT dispersion after obesity drug sibutramine.
    Yalcin AA; Yavuz B; Ertugrul DT; Algul B; Yilmaz H; Deveci OS; Kucukazman M; Ata N; Demirel G; Dal K; Tutal E
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):832-5. PubMed ID: 20671571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The obesity pandemic--how did we get here?
    Malone M
    Ann Pharmacother; 2007 Sep; 41(9):1497-8. PubMed ID: 17652122
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study.
    Tyczynski JE; Oleske DM; Klingman D; Ferrufino CP; Lee WC
    Drug Saf; 2012 Aug; 35(8):629-44. PubMed ID: 22788234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use.
    Eroglu E; Gemici G; Bayrak F; Kalkan AK; Degertekin M
    Int J Cardiol; 2009 Oct; 137(2):e43-5. PubMed ID: 18687492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials.
    Jordan J; Scholze J; Matiba B; Wirth A; Hauner H; Sharma AM
    Int J Obes (Lond); 2005 May; 29(5):509-16. PubMed ID: 15685250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [32-year-old patient with acute myocardial infarction possibly induced by the appetite suppressant sibutramine].
    Pöss J; Böhm M; Link A
    Dtsch Med Wochenschr; 2010 May; 135(19):965-8. PubMed ID: 20446231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
    James WP; Caterson ID; Coutinho W; Finer N; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Shepherd GM; Rode RA; Renz CL;
    N Engl J Med; 2010 Sep; 363(10):905-17. PubMed ID: 20818901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Withdrawal of sibutramine. Editorial is judgment in advance of the facts.
    Finer N;
    BMJ; 2010 Mar; 340():c1346. PubMed ID: 20219799
    [No Abstract]   [Full Text] [Related]  

  • 19. Withdrawal of sibutramine. Magic bullets now uncontrolled.
    Garrow JS
    BMJ; 2010 Mar; 340():c1351. PubMed ID: 20219800
    [No Abstract]   [Full Text] [Related]  

  • 20. Sibutramine--another flawed diet pill.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2010 Sep; 363(10):972-4. PubMed ID: 20818908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.